Semaglutide
SURMOUNT-5
Novo Nordisk · Phase 3 · Completed · Enrollment 751
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| 15 mg or MTD - Tirzepatide | 163 participants | 56 participants | 88 participants | n/r | 0 |
| 2.4 mg or MTD - Semaglutide | 167 participants | 80 participants | 88 participants | n/r | 0 |
A count stays a count. This page does not turn a count into a percent.